Vascular acrosyndromes in systemic sclerosis;Acrosyndromes sclérodermiques

Revue du Praticien

Volumn 52, Issue 17, 2002, Pages 1891-1895

  Carpentier, Patrick H ^a  

^a HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DEXTRAN DERIVATIVE; PROSTAGLANDIN;

FINGER; HOSPITALIZATION; HUMAN; NAIL DISEASE; PHYSIOTHERAPY; RAYNAUD PHENOMENON; REVIEW; SKIN CALCIFICATION; SKIN SCAR; SKIN ULCER; SYNDROME; SYSTEMIC SCLEROSIS; VASCULAR DISEASE;

CALCIUM CHANNEL BLOCKERS; FINGERS; HUMANS; NAILS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC; SKIN ULCER;

EID: 0036846666     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Carpentier PH, Laperrousaz P, Magne JL et al. Semiological analysis of Raynaud attacks. Int. Angiol. 1987; 6: 163-9.
2. Carpentier PH, Maricq HR. Microvasculature in systemic sclerosis. Rheum Dis Clin North America, 1990, 16, (1): 75-91.
3. Guilmot JL, Diot E, Lasfargues G, Boissier C. Phénomène de Raynaud et connectivites. Rev Prat 1998; 48: 1647-52.
4. Priollet P. Diagnostic et traitement du phénomène de Raynaud. Rev Prat 1998; 48: 1659-64.
5. Vayssairat M, Fiessinger JN, Housset E. Nécroses digitales des membres supérieurs. 86 cas. Nouv. Presse Med. 1977; 6: 931-4.
6. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001; 44: 1841-7.
7. Pope J, Fenlon D, Thompson A et al. Prazosin for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000; CD000956.
8. Dziadzio M, Denton CP, Smith R et al. Losartan therapy for Raynaud's phenomenon and scleroderma: Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum 1999; 42: 2646-55.
9. Vayssairat M. Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. J Rheumatol 1999; 26: 2173-8.
10. Pope J, Fenlon D, Thompson A et al. Iloprost and cicaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000; CD000953.
11. Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis. J Rheumatol 1992; 19: 1407-14.
12. Zachariae H, Halkier-Sorensen L, Bjerring P, Heickendorff L. Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis. Acta Derm Venereol 1996; 76: 236-8.
13. Ciompi ML, Bazzichi L, Melchiorre D, De Giorgio F, Bondi F, Puccetti L. A placebo-controlled study on urokinase therapy in systemic sclerosis. Biomed Pharmacother 1996; 50: 363-8.
14. Carpentier PH, Fabry R. Crénothérapie des maladies vasculaires. In P. Queneau (ed.) Médecins Thermale. Faits et Preuves. Masson, Paris, 2000: 102-15.
15. Filho JP, Sampaio-Barros PD, Parente JB et al. Rhythmic external compression of the limbs: A method for healing cutaneous ulcers in systemic sclerosis. J Rheumatol 1998; 25: 1540-3.
16. McCall TE, Petersen DP, Wong LB. The use of digital artery sympathectomy as a salvage procedure for severe ischemia of Raynaud's disease and phenomenon. J Hand Surg 1999; 24: 173-7.